LSE Health - Medical Technology Research Group and Department of Health Policy, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK.
LSE Health - Medical Technology Research Group and Department of Health Policy, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK.
J Cancer Policy. 2022 Dec;34:100352. doi: 10.1016/j.jcpo.2022.100352. Epub 2022 Aug 8.
To ensure the previous progress seen in cancer survival rates continues as we move through the 21st Century it is important to determine future effective policy related to oncology healthcare delivery and funding. Recent successes with, for example, the COVID vaccine response, the decision-making agility exhibited by governments and healthcare systems and the effective use of telehealth and real-world evidence highlight the progress that can be made with pooled efforts and innovative thinking. This shared approach is the basis for the European Beating Cancer Plan which outlines action points for governments and health systems for the period 2021-2025. It focuses on a whole government approach, centred on patients, maximising the potential of new technologies and insights across policy areas including employment, education, transport and taxation, enabling the tackling of cancer drivers in schools, workplaces, research labs, towns and cities and rural communities. Despite the plan there are still concerns that oncology policy has not adequately responded to the pace of innovation and the unique challenges generated by innovative oncological technologies. There needs to be focus on: gaining consensus on the most appropriate methods to assess and price combination therapies and cell and gene therapies, developing effective outcome-based payment models for personalised medicine and developing consensus on the ideal approach for multiple indication pricing. Finally, future policy needs to ensure pharmaceutical companies and other research organisations are adequately rewarded for innovation to ensure continued R&D and the development of innovative oncological products.
为了确保我们在 21 世纪继续取得癌症存活率方面的先前进展，确定与肿瘤学医疗保健提供和资金有关的未来有效政策非常重要。最近在 COVID 疫苗应对、政府和医疗保健系统表现出的决策灵活性以及远程医疗和真实世界证据的有效利用方面取得了成功，突出了可以通过共同努力和创新思维取得的进展。这种共同方法是《欧洲抗癌计划》的基础，该计划概述了 2021-2025 年期间政府和卫生系统的行动要点。它侧重于一种以患者为中心的整体政府方法，最大限度地发挥新技术和跨政策领域（包括就业、教育、交通和税收）的见解潜力，使癌症在学校、工作场所、研究实验室、城镇和城市以及农村社区的驱动因素得到解决。尽管有该计划，但仍有人担心肿瘤学政策没有充分应对创新步伐以及创新肿瘤学技术带来的独特挑战。需要关注：就评估和定价联合疗法以及细胞和基因疗法的最合适方法达成共识，为个性化药物制定有效的基于结果的支付模式，并就多种适应症定价的理想方法达成共识。最后，未来的政策需要确保制药公司和其他研究组织因创新而得到充分奖励，以确保持续的研发和创新肿瘤学产品的开发。
